EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Chronic oral anticoagulation and contemporary outcomes of elective endovascular aortic aneurysm repair

Lara Dias, Leandro Nóbrega, José Oliveira-Pinto, Armando Mansilha

Hellenic Journal of Vascular and Endovascular Surgery · 2023

DOI: 10.59037/akkqth98 ↗
AbstractBibliografische Angaben

Abstract

Introduction and Objective Impact of chronic anticoagulation on endoleak risk after EVAR has been conflicting. Our aim was to assess how anticoagulation at time of EVAR can impact endoleak risk after EVAR. Methods A retrospective review of all patients submitted to elective EVAR for infra-renal abdominal aortic aneurysms from January 2018 to December 2021 was performed. Patients with isolated iliac aneurysms, complex repair (F/BEVAR) or presenting with rupture or symptomatic aneurysms were excluded. Patient demographics, procedural and post-operative outcomes were reviewed. Outcomes were defined according the SVS Reporting standards for endovascular aortic aneurysm repair. Primary endpoint was the impact of chronic anticoagulation type II EL after EVAR. Post-operative complications and reinterventions were also addressed. Survival analysis was preferred to compare endoleak occurrence among groups. Cox regression was performed to evaluated independent anticoagulation effect on type II EL occurrence. Results A total of 99 patients were identified, with 19 (19.2%) of these on chronic oral anticoagulation at time of EVAR. All anticoagulated patients were male and were older than non-anticoagulated patients (mean age 76.4 ±8.5 vs 71.4 ± 7.9, p=0.017). Patients on oral anticoagulation were more likely to have cardiac arrythmia, with no other differences regarding baseline comorbidities. There were no differences in type of anaesthesia or intra-operative complications. Four patients on anticoagulation were submitted to an additional procedure in the first 30-day (21.1% vs 7.5%, p=0.096). Mean follow-up was 18,9 ± 15,25 months. During follow-up, a total of 10 patients developed type II endoleak (EL): four patients in the anticoagulation group (21,1%), vs 6 non-anticoagulated patients (7,5%), p=0.032). After adjustment for age and gender, anticoagulated patients were at greater risk for type II EL (HR: 8.92, CI95% 1.65-48.12, p=0,011). Three-year overall survival was worst for anticoagulated patients, 49,1% vs 87,7%, p=

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →